Acute coronary syndrome in the oncology patient: An unpredictable event?

Afonso Félix-Oliveira, Nélson Vale, Sérgio Madeira, Miguel Mendes

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


5-Flurouracil is a first-line agent in several cancer-therapy regimens. Cardiotoxicity is common, with coronary artery disease being an important risk factor. We report the case of an acute coronary syndrome presumably induced by 5-FU, in a patient with previously unknown and asymptomatic coronary artery disease, with and estimated intermediate risk for cardiovascular events. Pre-chemotherapy risk evaluation and optimal patient care are still not standardized in this clinical scenario.

Original languageEnglish
Article number791
JournalRevista Portuguesa de Cardiologia
Issue number9
Early online date23 May 2018
Publication statusPublished - Sep 2018


  • 5‐FU
  • Angina Pectoris
  • Angina pectoris
  • Cardiotoxicidade
  • Cardiotoxicity


Dive into the research topics of 'Acute coronary syndrome in the oncology patient: An unpredictable event?'. Together they form a unique fingerprint.

Cite this